 Shuttle Pharmaceuticals SHPH, has announced that it has been awarded patents in the U.S. and Hong Kong for its radiation sensitizing HDAC inhibitor technology platform, which is focused on reducing side effects and improving outcomes for cancer patients treated with radiation therapy. Approximately 800,000 patients in the US are treated with radiation therapy for their cancers. 